Latest Financial Health News

Infinity Mining Limited reported a net cash outflow of A$143,000 for the September quarter, with cash reserves dwindling to A$30,000. The company is pursuing cost-saving measures and an imminent capital raising to secure its short-term future.

Australia United Mining reported no new activity at its NSW Sofala joint venture but revealed promising high-grade gold assays in Queensland’s Queenslander workings, alongside disappointing results at Goldsmith North. The company faces tight cash reserves but has secured related-party loan facilities to support ongoing operations.

True North Copper reported significant copper-gold and copper-cobalt-silver discoveries in its September 2025 quarter, reinforcing its growth strategy and financial strength heading into 2026.

Saunders International anticipates a weaker first half in FY26 amid ongoing operational challenges but gains momentum with major contracts and strategic expansion into New South Wales.

Echelon Resources reported a solid quarter with production gains at Maari and Mahato fields, supported by new wells and a strategic gas sales agreement, while maintaining shareholder returns through dividends.

Cobram Estate Olives Limited has reported a record-breaking FY2025, driven by strong sales growth in Australia and the USA, alongside a $178 million equity raise to accelerate its Californian olive grove expansion.

Otto Energy reported an 11% rise in oil production and a solid US$2 million net operating cash inflow in Q3 2025, alongside key executive and board changes.

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

ACDC Metals reports promising mineralogy results from its Goschen Central Project, highlighting valuable rare earth elements and heavy minerals. The company maintains a solid cash balance and advances its retention licence application, positioning itself well in the evolving rare earth sector.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.

Articore Group has initiated an on-market share buy-back of up to 10% of its issued capital, signaling renewed confidence in its turnaround and long-term growth prospects.